144 results
8-K
EX-99.1
BCDA
BioCardia Inc.
27 Mar 24
BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results
4:07pm
supportive Helix™ Biotherapeutic Delivery and Morph Access Innovations businesses.”
RECENT BUSINESS HIGHLIGHTS:
CardiAMP® Autologous Cell Therapy … biotherapeutic delivery partnerships are expected in 2024.
Morph Access Innovations Business
BioCardia expects to obtain FDA approval for a product family
8-K
EX-99.1
BCDA
BioCardia Inc.
13 Mar 24
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership
7:00am
commercial access to an off-the-shelf heart regeneration treatment.”
“StemCardia’s team encompasses recognized leaders in the field of cardiac
8-K
EX-99.1
ka1hslg1a
3 Jan 24
Business Development Update for Shareholders
7:00am
8-K
qxdz3d9
3 Jan 24
Business Development Update for Shareholders
7:00am
8-K
EX-1.1
h2n6vp79
6 Dec 23
Other Events
6:05am
424B5
82xxy1 211
6 Dec 23
Prospectus supplement for primary offering
6:03am
424B5
b97r p1izf4e
17 Nov 23
Prospectus supplement for primary offering
5:25pm
8-K
EX-99.1
1v9s5s
16 Nov 23
Securities Purchase Agreement
5:15pm
8-K
EX-99.1
wjzjx32ca
8 Nov 23
Biocardia Reports Third Quarter 2023 Business Highlights and Financial Results
4:08pm
8-K
EX-99.1
tsptxzm8mn10f1rr2f
9 Aug 23
Biocardia Reports Second Quarter 2023 Business Highlights and Financial Results
4:08pm
8-K
EX-99.1
7o54s3 xcx8
5 Jul 23
BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency
7:00am
424B5
lue66aurbwnt mqd9
22 Jun 23
Prospectus supplement for primary offering
8:33am
8-K
EX-99.1
m4m6cr1z
21 Jun 23
Securities Purchase Agreement
5:23pm
8-K
EX-99.1
pkq983zpvcc55sj
20 Jun 23
Regulation FD Disclosure
5:00pm